| Bioactivity | CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC50: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC50 of 0.15 μM[1]. |
| Target | IC50: 7.4 nM (CDK7) |
| Name | CDK7-IN-26 |
| Formula | C22H22FN6OPS |
| Molar Mass | 468.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955. |